Drug side effect reports have skyrocketed over recent years, leading researchers to reconsider the value of FDA's adverse event system.
By Laurence Banville
The US Food & Drug Administration received over 1 million reports of pharmaceutical drug side effects and complications in 2015, marking a five-fold increase in adverse event reporting over the last 12 years. The agency's statistics have not been finalized for 2016, but analysts from the Milwaukee Journal Sentinel and Medpage Today expect last year's total to match the record set in 2015.
Side Effect Data Gets Renewed AttentionIn 2004, patients and doctors filed only 206,000 reports of adverse events linked to prescription drugs. Those numbers, a new analysis has found, have been growing steadily over the years, reaching around 1.2 million by 2015. At the same time, public health researchers and pharmaceutical manufacturers have been presented with an unprecedented amount of data to identify emerging safety risks. The information, however, remains untapped, experts at Medpage Today say, in part because the FDA discourages investigators from using it.
The FDA has long held that adverse event reports cannot be considered evidence of a causal link between any drug and suspected side effects, plastering each report with warnings that dissuade researchers from using the data to estimate risks. Those qualifications, however, haven't prevented the agency itself from using adverse event data to monitor safety issues. In 2015, for example, hundreds of side effect reports tipped FDA researchers off to a serious issue with the migraine patch Zecuity, which was soon taken off the market.
Despite Flaws, FDA System Given Second LookThere's no doubt that FDA adverse event reports present an incomplete picture of drug side effects. In fact, the Government Accountability Office condemned the federal agency's postmarketing safety program in 2005, estimating that the system captured only 1% to 10% of the actual problems experienced by patients. Critics of the FDA's system point out that reporting is usually voluntary. Doctors and patients are allowed to submit, but only pharmaceutical manufacturers are required to do so. Joseph Ross, MD, an associate professor at Yale's School of Medicine has tried to use adverse event reports in his own research, but found the system "very, very clumsy."
Rapid increases in reporting, though, have prompted some independent researchers to rethink how the data should be used. "Sheer numbers have some scientific weight," says Thomas Moore, Senior Scientist at the Institute for Safe Medication Practices. "If 500 people report a problem, it is unlikely that they are all wrong." Moore has a point. In the analysis performed by Medpage Today and the Milwaukee Journal Sentinel, seven out of the ten most-reported drugs had already been slapped with "black box" labels, the FDA's harshest warning. Those same ten drugs account for one in five adverse event reports submitted between 2013 and 2015.